At the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, a key focus will be precision therapy – targeting genetic drivers of cancer with highly selective medicines. By developing medicines for patients most likely to benefit, precision therapy offers the potential for truly transformative effects. At Blueprint Medicines, we focus on designing medicines that exquisitely target the underlying molecular causes of disease. Specifically, our strategy is to create therapies that bind to a target kinase – which is a proven driver of cancer and rare diseases – and block it from perpetuating cell growth signals. Our precision therapy approach offers the potential for improved potency, reduced off-target safety events and enhanced probabilities of clinical success.
Leading up to the ASCO meeting, our clinical development experts discussed the important role of precision therapy across multiple cancers and how we’re advancing this promising field of medicine: